|
Barbara A. Jones is a partner in the law firm of McDermott Will & Emery LLP based in the Firm's Boston office, where she heads the Boston Securities Practice Group and is a member of the firm wide committee on Securities and Financial Transactions. She maintains a diverse corporate and securities law practice across industry groups, emphasizing complex international and domestic transactions, including private and public financings, PIPEs, SPACs, alternative exit strategies, dual listings, mergers and acquisitions and licensing transactions. Her work extends to complex regulatory reporting and compliance issues arising in connection with her transactional work and representation of public listed companies. She has regularly served as counsel to leading investment banks, financial institutions and private equity groups, as well as public and private companies in life sciences and biotechnology, information technology, energy, telecommunications, media, entertainment and sports. Barbara is also active in the representation of professional and Olympic athletes and sports-related organizations.
Barbara has extensive experience in international corporate finance, including private equity, public and private offerings of equity and debt securities, dual listings, mergers and acquisitions and government privatizations, having practiced in London from 1990 through 2003. She headed the international capital markets practice of a major US law firm in London from 1999-2003 before relocating to Boston, Massachusetts in mid-2003. From 1997-1999, she served as vice-president and assistant general counsel and regional counsel for capital markets with J.P. Morgan Securities Ltd. in Europe, the Middle East and Africa. In addition, in recent years she has been actively involved in representing issuers, private equity groups and investment banks in the greater Asian markets.
Barbara is currently the vice-chair of the ABA’s Subcommittee on International Securities Matters and will begin a three-year term as chair in August 2008. She is a frequent speaker at conferences relating to cross-border securities matters and alternative financing strategies. She was a member of the ABA working committee that prepared the ABA’s comment letter in response to the SEC’s Securities Offering Reform proposals in 2004. Barbara has been recognized by Chambers USA 2005 as a leading lawyer in Corporate/M&A and The Legal 500 2007 for her work in private equity..
Barbara is admitted to practice in California and Massachusetts.
Representative Experience:
Representation of the international underwriters in connection with public offerings and Rule 144A placements by large multinational corporations, including initial public offerings, follow-on offerings, secondary offerings, block trades, accelerated bookbuilds, PIPES, government privatizations, dual-listings and initial U.S. listings
Representation of an international pharmaceutical company in connection with its $600 million SEC-registered open offer in the U.S. and U.K. and secondary offering
Representation of various international companies in connection with the establishment of a multi-billion dollar commercial paper programs
Representation of a major international public corporation in its multi-billion dollar synthetic merger and dual-listing with an Australian public company plc, including the obtaining of special SEC consents in connection therewith
Representation of a leading international public freight forwarding company in connection with its $5 billion merger with a competitor (including the delisting from the American Stock Exchange)
Representation of a dual-listed (LSE/NYSE) financial services holding company in connection with its initial public offering and listing in the United States and its ongoing U.S. regulatory compliance and reporting requirements, including Guides 3 and 6 and Basel capital-requirement guidelines
Representation of a leading international (New York-based) NYSE-listed financial institution in connection with its depository and custodial activities and related SEC filing and reporting requirements
Representation of a Chinese precision steel company in connection with its reverse merger and NASDAQ listing, relating PIPE and registered direct offerings and SEC compliance
Representation of a leading international (UK-based) dual-listed (LSE/NYSE) financial institution in connection with its U.S. securities reporting and compliance matters, including Guide 3 requirements
Representation of a leading Portuguese bank in connection with its initial public offering in the United States, NYSE-listing, and related ongoing U.S. regulatory compliance and reporting requirements, including Guides 3 and 6 and Basel capital-requirement guidelines
Representation of a leading Swedish financial institution in connection with its securities offerings in the U.S., NYSE listing and its ongoing U.S. regulatory compliance and reporting requirements, including Guide 3
Representation of the underwriters in connection with the proposed spin-off and international offering of a division of a leading international financial institution based in the United Kingdom
Representation of a major multinational oil company in connection with its proposed spin-off of an American operating division, formation of a master limited partnership and listing on the NYSE
Representation of a private equity group in connection with special Securities Exchange Act compliance issues and American Stock Exchange listing issues arising out of a portfolio company investment
Representation of an international publishing group in connection with the private placement of equity securities
Representation of a Scandinavian private equity group in connection with its €430 million multi-jurisdictional acquisition of an international division of a European-based manufacturing group
Representation of a substantial shareholder of a NASDAQ-listed company in connection with a contested proxy solicitation
Representation of an Australian-listed life sciences company in its acquisition of a medical device business from a division of a major international pharmaceutical company and ongoing U.S. corporate and securities laws matters
Representation of a NASDAQ-listed Chinese biotechnology company in connection with its U.S. securities laws compliance issues
Representation of a NASDAQ-listed biotechnology company in its PIPE offering of $16 million of convertible notes and warrants
Representation of various placement agents in private placements, PIPEs and Registered Direct transactions for life sciences, information technology and energy companies
Representation of a NASDAQ-listed biotechnology company in its public offering of $90 million of senior convertible notes
Representation of a UK-based international wireless technology company in connection with its proposed initial public offering and dual-listing
Representation of early stage companies in connection with initial funding requirements and business development strategies
Representation of a sports and entertainment marketing company in connection with various celebrity merchandising and distribution arrangements
Education:
Pepperdine University School of Law, J.D. (magna cum laude), 1989
Michigan State University, B.A. (honors), 1974 | 